mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 801–900 of 1,062
Consequences of NMDA Receptor Deficiency Can Be Rescued in the Adult Brain
Mielnik, C. A., Binko, M. A., Chen, Y., Funk, A. J., Johansson, E. M., Intson, K., Sivananthan, N., Islam, R., Milenkovic, M., Horsfall, W., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-020-00859-4 · Cited by 63
Pochwat, B., Sowa-Kućma, M., Kotarska, K., Misztak, P., Nowak, G., & Szewczyk, B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3671-6 · Cited by 63
Kadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.027 · Cited by 62
Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
Raber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
Gilbert, J. R., Yarrington, J. S., Wills, K. E., Nugent, A. C., & Zarate, C. A. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy041 · Cited by 55
“Due to a blockade of NMDA receptors on postsynaptic excitatory neurons, excess synaptic glutamate is primarily taken up by AMPA receptors, thereby activating neuroplasticity-related signaling pathways (including mammalian target of rapamycin complex 1 (Li et al., 2010; Li et al., 2011) and brain-derived neurotrophic f…”
BackgroundMuscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.710338 · Cited by 63
“(28, 76) in the premise that the CUS mouse model of depression produced rat brain atrophy and maladaptive remodeling of dendrites in the same brain regions affected in humans with TRD.”
BackgroundResultInfluentialEvidence for Impaired Neocortical Synaptic Plasticity in Bipolar II Disorder
Elvsåshagen, T., Moberget, T., Bøen, E., Boye, B., Englin, N. O. A., Pedersen, P. Ø., Andreassen, O. A., Dietrichs, E., Malt, U. F., & Andersson, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.026 · Cited by 64
Denk, M. C., Rewerts, C., Holsboer, F., Erhardt, A., & Turck, C. W. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010128 · Cited by 62
Liu, R.-J., Ota, K. T., Dutheil, S., Duman, R. S., & Aghajanian, G. K. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.70 · Cited by 62
“…of the mammalian target of rapamycin complex 1 (TORC1) pathway in the medial prefrontal cortex (mPFC), triggering dendritic translation of synaptic proteins that are then incorporated into stable synaptic spines in apical dendrites that can persist a week or longer (Li et al, 2010; Li et al, 2011).”
BackgroundMethodResultSelf-citationPerfusion deficits, inflammation and aging precipitate depressive behaviour
Popa‐Wagner, A., Bugă, A. M., Tica, A. A., & Albu, C. V. (2014) · Biogerontology · doi:10.1007/s10522-014-9516-1 · Cited by 62
Meylan, E. M., Breuillaud, L., Seredenina, T. S., Magistretti, P. J., Halfon, O., Luthi‐Carter, R., & Cardinaux, J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.116 · Cited by 62
Short‐ and long‐term antidepressant effects of ketamine in a rat chronic unpredictable stress model
Jiang, Y., Wang, Y., Sun, X., Lian, B., Sun, H., Wang, G., Du, Z., Li, Q., & Sun, L. (2017) · Brain and Behavior · doi:10.1002/brb3.749 · Cited by 62
“…trajectory are thought to enhance glutamatergic signaling and dopamine release in the prefrontal cortex by reducing excitatory input upon gamma amino butyric acid neurons, subsequently leading to hyperactivity of corticolimbic pathways (Li et al., 2010; Moghaddam, Adams, Verma, & Daly, 1997).”
BackgroundHippocampal mTOR signaling is required for the antidepressant effects of paroxetine
Xu, D., Sun, Y., Wang, C., Wang, H., Wang, Y., Zhao, W., Bao, G., Wang, F., Cui, Z., & Jiang, B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.008 · Cited by 62
“Since Li et al. reported in 2010 that ketamine produced rapid antidepressant effects via activating the mTOR pathway in the PFC (Li et al., 2010), mTOR has been becoming a popular target in depression research.”
BackgroundMethodResultInfluentialKohtala, S., Theilmann, W., Rosenholm, M., Penna, L., Karabulut, G., Uusitalo, S., Järventausta, K., Yli-Hankala, A., Yalcin, I., Matsui, N., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1364-6 · Cited by 60
Molecular insights into psychedelic drug action
Slocum, S. T., DiBerto, J. F., & Roth, B. L. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15540 · Cited by 62
“Ketamine, a hallucinogenic dissociative with rapid- acting antidepressant effects, similarly induces spine alterations following acute administration (Li et al., 2010).”
BackgroundKetamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
“Previous studies have shown a similar prolonged increase in synapsin I levels in the prefrontal cortex at 72 h after ketamine administration, accompanied by increased synaptogenesis (Li et al., 2010, 2011).”
BackgroundResultInfluentialRapamycin attenuates the expression of cocaine‐induced place preference and behavioral sensitization
Bailey, J., Ma, D., & Szumlinski, K. K. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00311.x · Cited by 61
“Recently, Li et al. (2010) observed mTOR pathway activation in the PFC from 30 minutes to 1 hour after an i.p. injection of the NMDA receptor antagonist ketamine, and further demonstrated the synaptogenic and antidepressant behavioral effects of ketamine to be sensitive to intra-PFC rapamycin.”
BackgroundLino de Oliveira, C., Bolzan, J. A., Surget, A., & Belzung, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107515 · Cited by 61
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Shi, X., Zhou, X., Chen, G., Luo, W., Zhou, C., He, T.-J., Naik, M. T., Jiang, Q., Marshall, J. J., & Cao, C. (2024) · Science Signaling · doi:10.1126/scisignal.adn4556 · Cited by 61
“The PI3K- Akt-mTOR pathway is implicated in the pathogenesis of depression ( 53 ), and drugs exhibiting rapid antidepressant action have been shown to increase mTOR-dependent synapse formation ( 54 ).”
BackgroundForkhead box O transcription factors as possible mediators in the development of major depression
Wang, H., Quirion, R., Little, P. J., Cheng, Y., Feng, Z., Sun, H., Xu, J., & Zheng, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.020 · Cited by 61
“On the other hand, recent studies suggest that the rapid-acting antidepressant and synaptogenic effects of ketamine are dependent upon mToR activity in the medial prefrontal cortex (Li et al., 2010).”
Liu, B., Luo, L., Liu, X., Geng, D., Liu, Q., & Yi, L. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3690-3 · Cited by 62
Sabino, V., Narayan, A. R., Zeric, T., Steardo, L., & Cottone, P. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.02.030 · Cited by 56
Trujillo, K. A., Smith, M. L., Sullivan, B., Heller, C. Y., Garcia, C., & Bates, M. L. S. (2011) · ILAR Journal · doi:10.1093/ilar.52.3.366 · Cited by 61
“2007), and studies have shown that AMPA receptor (AMPAR1) antagonists attenuate certain behavioral and neurochemical effects of dissociatives (Hauber and Andersen 1993; Hauber and Waldenmeier 1994; Li et al. 2010; Maeng et al. 2008; Takahata and Moghaddam 2003).”
BackgroundInfluentialBiological substrates underpinning diagnosis of major depression
Sibille, E., & French, B. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000436 · Cited by 50
“ketamine-related NMDA antagonism, does not rely on direct evidence for dysregulated NMDA function in major depression, but rather on clinical observations and recently on a growing number of rodent pre-clinical studies (Li et al., 2010; Autry et al., 2011).”
BackgroundCostemale-Lacoste, J.-F., Guilloux, J., & Gaillard, R. (2016) · L Encéphale · doi:10.1016/j.encep.2016.02.003 · Cited by 61
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44
Dalmagro, A. P., Camargo, A., Rodrigues, A. L. S., & Zeni, A. L. B. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108843 · Cited by 61
Goswami, D. B., Jernigan, C. S., Chandran, A., Iyo, A. H., May, W. L., Austin, M. C., Stockmeier, C. A., & Karolewicz, B. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.010 · Cited by 59
“In addition, it has been demonstrated that a single dose of these antagonists rapidly reverses the chronic stress-induced behavioral and synaptic deficits in an mTOR-dependent manner (Li et al., 2010), showing that mTORregulated protein synthesis and the glutamatergic system are tightly connected, and that a misbalanc…”
InfluentialIglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J. M., & Irwin, S. A. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.05.005 · Cited by 60
Zhan, Y., Zhang, B., Zhou, Y., Zheng, W., Liu, W., Wang, C., Li, H., Chen, L., Yu, L., Walter, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.071 · Cited by 60
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
“A single dose of ketamine has also been reported to produce rapid and sustained antidepressant effects in several animal models (Autry et al. 2011; Li et al. 2010; Maeng et al. 2008).”
BackgroundREDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury
Morquette, B., Morquette, P., Agostinone, J., Feinstein, E., McKinney, R. A., Kolta, A., & Di Polo, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.149 · Cited by 60
“in the regulation of dendritic spine morphology, synaptogenesis and synaptic plasticity.(10,11) The emerging developmental role of mTOR in the regulation of dendritic dynamics prompted”
BackgroundAntidepressant Action on Mitochondrial Dysfunction in Psychiatric Disorders
Adzic, M., Brkic, Z., Bulajic, S., Mitic, M., & Radojcic, M. B. (2016) · Drug Development Research · doi:10.1002/ddr.21332 · Cited by 60
“Although most ADs reduced the metabolic function of mitochondria, redox function increased in conditions that facilitate synaptic functions [Li et al., 2010].”
BackgroundKopelman, J., Keller, T. A., Panny, B., Griffo, A., Degutis, M., Spotts, C., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02451-0 · Cited by 60
“Activity in these regions has been shown to be altered in depressed subjects, with studies of BA10 (and nearby related PFC regions) showing hyperactivation to reward-related cues and hypoactivation to negative affective cues (e.g., negatively valanced faces) in depressed subjects relative to controls [46].”
BackgroundInfluentialSubanesthetic Ketamine Reactivates Adult Cortical Plasticity to Restore Vision from Amblyopia
Grieco, S. F., Qiao, X., Zheng, X., Liu, Y., Chen, L., Zhang, H., Yu, Z., Gavornik, J. P., Lai, C., Gandhi, S. P., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.07.008 · Cited by 60
Scheepstra, K. W. F., Mizee, M. R., van Scheppingen, J., Adelia, A., Wever, D. D., Mason, M. R. J., Dubbelaar, M. L., Hsiao, C.-C., Eggen, B. J. L., Hamann, J., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.04.020 · Cited by 60
Daniele, S., Da Pozzo, E., Zappelli, E., & Martini, C. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.006 · Cited by 56
Psychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects
Lester, H. A., Miwa, J. M., & Srinivasan, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.020 · Cited by 53
“5 mg/kg (5); in mouse, the effective dose was 3 mg/kg (6).”
Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
Yang, B., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw080 · Cited by 57
“It is reported that other NMDA receptor antagonists, such as Ro 25–6981, ifenprodil (GluN2B antagonist), CPP, and 7-chlorokynurenic acid (a prodrug of glycine site antagonist 7-chlorokynurenic acid) showed sustained (24 hours) antidepressant effects in rodents (Li et al., 2010; Autry et al., 2011; Miller et al., 2014;…”
BackgroundSathyanesan, M., Haiar, J. M., Watt, M. J., & Newton, S. S. (2017) · Stress · doi:10.1080/10253890.2017.1298587 · Cited by 60
Humo, M., Ayazgök, B., Becker, L. J., Waltisperger, E., Rantamäki, T., & Yalçın, İ. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109898 · Cited by 60
The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication
Andrashko, V., Novak, T., Brunovsky, M., Klirova, M., Sos, P., & Horacek, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00844 · Cited by 48
“Preclinical data suggested that a ketamineinduced elevation of synaptic proteins (such as synapsin I, PSD95 and GluR1) could be initially observed 2 h after the application and remained increased up to 7 days (8).”
BackgroundN -Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
Ahmed, H., Haider, A., & Ametamey, S. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811234 · Cited by 60
Yang, W., Chini, M., Pöpplau, J. A., Formozov, A., Dieter, A., Piechocinski, P., Rais, C., Morellini, F., Sporns, O., Hanganu‐Opatz, I. L., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001146 · Cited by 61
“It was further shown that sub-anesthetic, antidepressant doses of ketamine enhance spine density in the prefrontal cortex [90,91], similar to our study of CA1 neurons.”
ResultBridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Topol, A., English, J. A., Flaherty, E. K., Rajarajan, P., Hartley, B. J., Gupta, S., Desland, F. A., Zhu, S., Goff, T., Friedman, L., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.118 · Cited by 59
Kiselycznyk, C., Jury, N. J., Halladay, L. R., Nakazawa, K., Mishina, M., Sprengel, R., Grant, S. G. N., Svenningsson, P., & Holmes, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.023 · Cited by 56
“These data demonstrate a key contribution of the mPFC to the antidepressant-like effects of Ro 25-6981, consistent with prior evidence that the antidepressant-like effects of Ro 25-6981 and ketamine are associated with synaptogenesis and increases in synaptic excitability and protein expression, including GluA1, PSD-9…”
BackgroundMethodResultInfluentialmTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.037 · Cited by 59
“8) (Li et al., 2010).”
BackgroundMethodResultInfluentialHascup, K. N., Hascup, E. R., Humeidan, M., Glaser, P. E. A., Yoshitake, T., Mathé, A. A., Gerhardt, G. A., & Kehr, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.60 · Cited by 60
“Sub-anesthetic doses of ketamine, an N-methyl-D-aspartate receptor antagonist, have antidepressant effects with immediate onset of action (Maeng and Zarate, 2007; Berman et al, 2000) probably due to its ability to increase synaptogenesis (Li et al, 2010).”
BackgroundDuclot, F., Perez-Taboada, I., Wright, K. N., & Kabbaj, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.022 · Cited by 52
“antidepressant effects consistent throughout the literature (Carrier and Kabbaj, 2013; Li et al., 2010).”
BackgroundInfluentialZhou, X., Liu, L., Zhang, Y., Pu, J., Yang, L., Zhou, C., Yuan, S., Zhang, H., & Xie, P. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.038 · Cited by 59
“Additionally, ketamin, a glutamate Nmethyl-D-aspartic acid receptor antagonist, was reported to have antidepressant actions (Li et al., 2010), which also indicated that abnormalities in the glutamatergic system may associate with the pathophysiology of depression.”
Ohta, K., Suzuki, S., Warita, K., Kaji, T., Kusaka, T., & Miki, T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13977 · Cited by 60
“Several studies indicate that ERK signaling pathways stimulate mammalian target of rapamycin signaling, which up-regulates expression of synaptic proteins such as PSD95 and GluR1 and promote spine formation (Li et al. 2010; Winter et al. 2011).”
BackgroundReus, G. Z., de Moura, A. B., Silva, R. H., Resende, W. R., & Quevedo, J. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170630164715 · Cited by 49
Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy
Jiang, C., Lin, W.-J., & Salton, S. R. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1124-0 · Cited by 55
Zheng, W., Zhou, Y., Liu, W.-J., Wang, C., Zhan, Y., Li, H.-Q., Chen, L., Li, M. D., & Ning, Y. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827811 · Cited by 59
Zhuo, J.-Y., Chen, B., Sun, C., Jiang, T., Chen, Z., Liu, Y., Nie, J., Yang, H., Zheng, J., Lai, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110115 · Cited by 61
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C. H., Li, X., Chaki, S., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0705-0 · Cited by 59
Self-citationWang, A., Zou, X., Wu, J., Ma, Q., Yuan, N., Ding, F., Li, X., & Chen, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.590068 · Cited by 59
Self-citationLawford‐Smith, H. (2015) · Journal of Social Ontology · doi:10.1515/jso-2015-0008 · Cited by 60
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
“The specific sequence from ketamine infusion to improved mood, cognition, and behavior includes: (1) increased glutamate release; (2) early activation and upregulation of AMPA receptors; and (3) activitydependent release of BDNF (Li et al. 2010; Maeng and Zarate 2007).”
Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity
Ma, Z. Z., Guzikowski, N. J., Kim, J.-W., Kavalali, E. T., & Monteggia, L. M. (2025) · Science · doi:10.1126/science.abb6748 · Cited by 50
Preclinical Evidence of Rapid-Onset Antidepressant-Like Effect in Radix Polygalae Extract
Shin, I.-J., Son, S. U., Park, H., Kim, Y., Park, S. H., Swanberg, K. M., Shin, J.-Y., Ha, S.-K., Cho, Y., Bang, S. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088617 · Cited by 58
New genetic insights highlight ‘old’ ideas on motor dysfunction in dystonia
Goodchild, R. E., Grundmann, K., & Pisani, A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.09.003 · Cited by 64
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 100
“…valproic acid, lamotrigine, and ketamine) mitigated decrements in BDNF in MDs (Chen et al., 2015; Fukumoto et al., 2001; Gama et al., 2007; Garcia et al., 2008; Hashimoto et al., 2002; Ikenouchi-Sugita et al., 2009; Li et al., 2010a; Nibuya et al., 1996; Polyakova et al., 2015; Reus et al., 2015).”
BackgroundMethodInfluentialFullana, N., Gasull-Camós, J., Tarrés-Gatius, M., Castañé, A., Bortolozzi, A., & Artigas, F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107914 · Cited by 57
BDNF receptor TrkB as the mediator of the antidepressant drug action
Casarotto, P., Umemori, J., & Castrén, E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1032224 · Cited by 50
“, 2007, 2011), the rapid-acting antidepressants ketamine (Li et al., 2010; Autry et al., 2011; Autry and Monteggia, 2012; Lepack et al., 2014) and scopolamine (Wohleb et al.”
BackgroundRapid-Acting Antidepressants: Mechanistic Insights and Future Directions
Gerhard, D. M., & Duman, R. S. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0139-8 · Cited by 52
Self-citationWalker, A. J., Foley, B. M., Sutor, S. L., McGillivray, J. A., Frye, M. A., & Tye, S. J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.026 · Cited by 56
“Consistent with previous literature (e.g. Li et al., 2010), significant reductions in immobility duration were observed in control animals administered ketamine (10 mg/kg), supporting an antidepressant-like response of ketamine in the FST. Interestingly, in animals pretreated with ACTH for 14 days,…”
ResultZorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
“org transmission are important in the effects of ketamine (71, 72), but it is unclear whether this involves specific downstream effects of AMPARs or the fact that depolarization mediated by AMPARs is important for activation of unblocked NMDARs.”
BackgroundInfluentialEnhancing ketamine translational pharmacology via receptor occupancy normalization
Shaffer, C. L., Osgood, S. M., Smith, D. L., Liu, J., & Trapa, P. E. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.008 · Cited by 57
“Importantly, as methodology is indication agnostic, it may be applied to understand the temporal RO relationship for reportedly antidepressant doses of ketamine in rats (Li et al., 2010) and humans (Berman et al.”
BackgroundMethodInfluentialJiang, B., Huang, C., Chen, X., Tong, L., & Zhang, W. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv010 · Cited by 57
“Here, we found that CSDS stress robustly decreased the BDNF expression in both the hippocampus and mPFC, two regions closely implicated in the pathogenesis of depression (Pittenger and Duman, 2008; Li et al., 2010).”
BackgroundSun, W., Suzuki, K., Toptunov, D., Stoyanov, S., Yuzaki, M., Khiroug, L., & Dityatev, A. E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00421 · Cited by 57
“Known effects of anesthetics range from suppressing neuronal firing and changing inter-cortical synchronization to altering the morphology of glial processes and affecting turnover rates of dendritic spines (Li et al., 2010; Huh and Cho, 2013; Pryazhnikov et al., 2018).”
BackgroundKim, J.-W., & Monteggia, L. M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112378 · Cited by 53
“In separate work, the mammalian target of rapamycin (mTOR) and its downstream signaling molecule, p70S6 kinase (S6K), have also been indicated as target molecules for ketamine’s rapid antidepressant effects [14, 15].”
BackgroundResultInfluentialDendritic protein synthesis in the normal and diseased brain
Swanger, S. A., & Bassell, G. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.003 · Cited by 46
“To investigate dendritic synthesis of AMPA receptor subunits, two laboratories used transected dendrites of hippocampal neurons and studied synthesis of exogenous GluA1 or GluA2 subunits fused to their 30 UTRs (Kacharmina et al., 2000; Ju et al., 2004).”
BackgroundInfluentialRadley, J. J. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00007 · Cited by 47
“The fact that GCs appear capable to exert widespread effects throughout the cortex, inclusive of sensorimotor regions (Liston and Gan, 2011), poses additional challenges in teasing apart neural circuits that underlie stress-related behavioral and physiological alterations.”
BackgroundCosti, S., Soleimani, L., Glasgow, A., Brallier, J., Spivack, J., Schwartz, J., Levitch, C. F., Richards, S., Hoch, M., Stade, E. C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0365-0 · Cited by 56
Li, Y., Jia, Y., Wang, D., Zhuang, X., Li, Y., Guo, C., Chu, H., Zhu, F., Wang, J., Wang, X., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0692-x · Cited by 56
Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Schiavone, S., Tucci, P., Mhillaj, E., Bové, M., Trabace, L., & Morgese, M. G. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.004 · Cited by 56
“Preclinical works have shown that a single treatment with ketamine increased number and function of spine synapses in the PFC (Li et al., 2010).”
BackgroundHo, M., Zhang, C., Zhang, L., Li, H., & Weinshilboum, R. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01302 · Cited by 57
“Activation of mTOR signaling is one of the most intensively studied of the processes that might contribute to the antidepressant effects of ketamine (Li et al., 2010; Harraz et al., 2016; Yang et al., 2018).”
BackgroundWu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., Xiao, L., & Kozorovitskiy, Y. (2021) · eLife · doi:10.7554/elife.64041 · Cited by 51
The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis
Du, R., Han, R., Niu, K., Xu, J., Zhao, Z., Lu, G., & Shang, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.813103 · Cited by 56
“Possible mechanisms underlying ketamine’s therapeutic effects could be related to ketamine rapidly increasing synaptic connections in the prefrontal cortex and reversing the behavioral and neuronal changes caused by chronic stress in rats, activating mammalian-targeted rapamycin signaling pathways and stimulating brai…”
BackgroundWorkman, E. R., Haddick, P. C. G., Bush, K., Dilly, G. A., Niere, F., Zemelman, B. V., & Raab-Graham, K. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.165 · Cited by 54
Boenigk, K., Echevarria, G. C., Nisimov, E., von Bergen Granell, A. E., Cuff, G. E., Wang, J., & Atchabahian, A. (2019) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000877 · Cited by 55
Unifying treatments for depression: an application of the free energy principle
Chekroud, A. M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00153 · Cited by 55
“In addition, from a neurobiological perspective, ketamine’s acute and sustained antidepressant effects have been hypothesized to depend on synaptogenesis (Li et al., 2010), in reminiscent fashion to monoaminergic antidepressants.”
BackgroundGrabski, M., Borissova, A., Marsh, B., Morgan, C. J. A., & Curran, H. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112629 · Cited by 55
Yang, C., Zhou, Z.-Q., Gao, Z.-Q., Shi, J.-Y., & Yang, J.-J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.022 · Cited by 55
Schumacher, F., Edwards, M. J., Mühle, C., Carpinteiro, A., Wilson, G. C., Wilker, B., Soddemann, M., Keitsch, S., Scherbaum, N., Müller, B. W., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102185 · Cited by 55
“Signaling of mTOR has been also shown to regulate synapse formation upon treatment with ketamine (38).”
Persistent pain alters AMPA receptor subunit levels in the nucleus accumbens
Su, C. H., D’amour, J. A., Lee, M. S., Lin, H.-Y., Manders, T. R., Xu, D., Eberle, S. E., Goffer, Y., Zou, A., Rahman, M., et al. (2015) · Molecular Brain · doi:10.1186/s13041-015-0140-z · Cited by 55
“However, glutamate signaling is known to play an important role in depression [50–52], and increased transmission through AMPA receptors have been shown to confer antidepressant effects [16, 53–55].”
BackgroundSpecific Roles of NMDA Receptor Subunits in Mental Disorders
Yamamoto, H., Hagino, Y., Kasai, S., & Ikeda, K. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150330142807 · Cited by 56
“GluN2B antagonists trigger their antidepressant effects by altering the activity of mTOR [110, 113], suggesting that inhibiting the activity of GluN2B subunit-containing NMDA receptors accounts for the majority of the antidepressant effects of ketamine.”
BackgroundInvestigational NMDA receptor modulators for depression
Szewczyk, B., Pałucha-Poniewiera, A., Poleszak, E., Pilc, A., & Nowak, G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638916 · Cited by 49
“[50] examined themolecular effects 2 h after ketamine administration but Autry et al.”
BackgroundInfluentialOh, J., Kim, Y.-K., Kim, S., Lee, B., Jang, J., Kwon, S., & Park, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-30337-5 · Cited by 55
Self-citationShi, Z., Zou, W., Zhu, Z., Xiong, Z., Li, S., Pan, D., & Zhu, Z. (2022) · Industrial Crops and Products · doi:10.1016/j.indcrop.2022.115283 · Cited by 55
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 56
“On the contrary, the antidepressant-like response to ketamine is abolished by infusion of rapamycin, an allosteric inhibitor of mTORC1, into the PFC of rodents, as measured by forced swim test and learned helplessness (Li et al., 2010; Li et al., 2011).”
BackgroundInfluentialWeckmann, K., Labermaier, C., Asara, J. M., Müller, M. B., & Turck, C. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.119 · Cited by 56
Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
Shinohara, R., Aghajanian, G. K., & Abdallah, C. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.006 · Cited by 54
Self-citationZhang, H., Sun, Y., Yau, S., Zhou, Y., Song, X., Zhang, H., Zhu, B., Wu, H., & Chen, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15847 · Cited by 55
“…clinical findings support this rapid and sustained antidepressant action of ketamine and extensive scientific investigations have been carried into underlying mechanism/s (Aguilar-Valles et al., 2021; Autry et al., 2011; Lapidus et al., 2014; Li et al., 2010; Maeng et al., 2008; Yang et al., 2018).”
BackgroundSabé, M., Sulstarova, A., Chen, C., Hyde, J., Poulet, E., Aleman, A., Downar, J. H., Brandt, V. C., Mallet, L., Sentissi, O., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105300 · Cited by 55
Adenosine signalling drives antidepressant actions of ketamine and ECT
Yue, C., Wang, N., Zhai, H., Yuan, Z., Cui, Y., Jing, Q., Zhou, Y., Fan, X., Wang, H., Wu, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-09755-9 · Cited by 55
“This dual-receptor signalling may provide a complementary upstream mechanism for previously implicated pathways, linking the action of ketamine to both mTOR activation and the induction of HOMER1A 5,20 .”
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.